To ask the Secretary of State for Health and Social Care, if he will take steps to increase the level of research into the use of psilocybin for the treatment of (a) depression, (b) addiction and (c) other chronic conditions on health inequalities; and if he will take steps to fund research into the use of psilocybin.
Answered on
20 July 2023
The Department commissions research through the National Institute for Health and Care Research (NIHR), who have invested £1.1 million in a randomised controlled trial to examine if it is feasible, safe and effective to use psilocybin to treat people with treatment-resistant depression. NIHR welcomes funding applications for research into any aspect of human health, including the use of psilocybin in the treatment of depression, addiction and other chronic conditions. Applications are subject to peer review and judged in open competition, with awards made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.
NIHR infrastructure is supporting psilocybin research via the NIHR King’s Clinical Research Facility and the NIHR Maudsley Biomedical Research Centre where researchers are developing and evaluating the efficacy and safety of psilocybin therapy for use in the National Health Service and other healthcare settings.